Related references
Note: Only part of the references are listed.FOXOs: masters of the equilibrium
Tianshu Gui et al.
FEBS JOURNAL (2022)
Archway Randomized Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration
Nancy M. Holekamp et al.
OPHTHALMOLOGY (2022)
THE ANGIOPOIETIN/TIE PATHWAY IN RETINAL VASCULAR DISEASES A Review
Jeffrey S. Heier et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2021)
Angiopoietin/Tie2 signalling and its role in retinal and choroidal vascular diseases: a review of preclinical data
Antonia M. Joussen et al.
EYE (2021)
Brolucizumab: a novel anti-VEGF humanized single-chain antibody fragment for treating w-AMD
Lorenzo Ferro Desideri et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2021)
Pericyte Insulin Receptors Modulate Retinal Vascular Remodeling and Endothelial Angiopoietin Signaling
Nele Warmke et al.
ENDOCRINOLOGY (2021)
Different Outcomes of Anti-VEGF Treatment for Neovascular AMD according to Neovascular Sutypes and Baseline Features: 2-Year Real-Life Clinical Outcomes
Alessandro Arrigo et al.
BIOMED RESEARCH INTERNATIONAL (2021)
An overview of gene therapies in the pipeline for ocular disorders
L. Ferro Desideri et al.
DRUGS OF THE FUTURE (2021)
Pericyte Insulin Receptors Modulate Retinal Vascular Remodeling and Endothelial Angiopoietin Signaling
Nele Warmke et al.
ENDOCRINOLOGY (2021)
Evolving role of anti-VEGF for diabetic macular oedema: from clinical trials to real life
Tarun Sharma
EYE (2020)
Faricimab: expanding horizon beyond VEGF
Ashish Sharma et al.
EYE (2020)
New Anti-VEGF Drugs in Ophthalmology
Claudio Campa
CURRENT DRUG TARGETS (2020)
Angiopoietin-2 blockade ameliorates autoimmune neuroinflammation by inhibiting leukocyte recruitment into the CNS
Zhilin Li et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
Real-Life Data in the Treatment of Neovascular Age-Related Macular Degeneration: Results from the Imaculaweb Registry Evaluated in a Single Italian Medical Retina Center
Massimo Nicolo et al.
OPHTHALMOLOGICA (2020)
Emerging drugs for the treatment of diabetic retinopathy
Elio Striglia et al.
EXPERT OPINION ON EMERGING DRUGS (2020)
Abicipar pegol: an investigational anti-VEGF agent for the treatment of wet age-related macular degeneration
Lorenzo Ferro Desideri et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2020)
Safety and Efficacy of Different Doses and Regimens of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration The AVENUE Phase 2 Randomized Clinical Trial
Jayashree Sahni et al.
JAMA OPHTHALMOLOGY (2020)
Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration The STAIRWAY Phase 2 Randomized Clinical Trial
Arshad M. Khanani et al.
JAMA OPHTHALMOLOGY (2020)
A Small Molecule Inhibitor of VE-PTP Activates Tie2 in Schlemm's Canal Increasing Outflow Facility and Reducing Intraocular Pressure
Guorong Li et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2020)
An update on conbercept to treat wet age-related macular degeneration
L. Ferro Desideri et al.
DRUGS OF TODAY (2020)
Simultaneous Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular Edema BOULEVARD Phase 2 Randomized Trial
Jayashree Sahni et al.
OPHTHALMOLOGY (2019)
Efficacy of simultaneous VEGF-A/ANG-2 neutralization in suppressing spontaneous choroidal neovascularization
Richard H. Foxton et al.
EMBO MOLECULAR MEDICINE (2019)
The Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration Results from the Randomized Phase 2 Ladder Clinical Trial
Peter A. Campochiaro et al.
OPHTHALMOLOGY (2019)
Clinical efficacy and safety of ranibizumab in the treatment of wet age-related macular degeneration
Lorenzo Ferro Desideri et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2019)
Tie-2/Angiopoietin pathway modulation as a therapeutic strategy for retinal disease
Rehan M. Hussain et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2019)
Bevacizumab in age-related macular degeneration: a randomized controlled trial on the effect of on-demand therapy every 4 or 8 weeks
Sankha Amarakoon et al.
ACTA OPHTHALMOLOGICA (2019)
Three-Year Follow-Up of Phase 1 and 2a rAAV.sFLT-1 Subretinal Gene Therapy Trials for Exudative Age-Related Macular Degeneration
Elizabeth P. Rakoczy et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2019)
A collagen IV-derived peptide disrupts α5β1 integrin and potentiates Ang2/Tie2 signaling
Adam C. Mirando et al.
JCI INSIGHT (2019)
Brolucizumab Anti-VEGF-A monoclonal antibody Treatment of age-related macular degeneration
L. Ferro Desideri et al.
DRUGS OF THE FUTURE (2019)
Signaling Pathways in Inflammation and Anti-inflammatory Therapies
Yiu To Yeung et al.
CURRENT PHARMACEUTICAL DESIGN (2018)
Real-world outcomes in patients with neovascular age-related macular degeneration treated with intravitreal vascular endothelial growth factor inhibitors
Hemal Mehta et al.
PROGRESS IN RETINAL AND EYE RESEARCH (2018)
Ischemic retinal vein occlusion: characterizing the more severe spectrum of retinal vein occlusion
Meiaad Khayat et al.
SURVEY OF OPHTHALMOLOGY (2018)
Optimizing Anti-VEGF Treatment Outcomes for Patients with Neovascular Age-Related Macular Degeneration
Charles C. Wykoff et al.
JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY (2018)
Age-related macular degeneration
Paul Mitchell et al.
LANCET (2018)
Gene therapy for age-related macular degeneration
Nicholas A. Moore et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2017)
Emerging vascular endothelial growth factor antagonists to treat neovascular age-related macular degeneration
Rehan M. Hussain et al.
EXPERT OPINION ON EMERGING DRUGS (2017)
Therapeutic targeting of the angiopoietin-TIE pathway
Pipsa Saharinen et al.
NATURE REVIEWS DRUG DISCOVERY (2017)
Plastic roles of pericytes in the blood-retinal barrier
Do Young Park et al.
NATURE COMMUNICATIONS (2017)
Global causes of blindness and distance vision impairment 1990-2020: a systematic review and meta-analysis
Seth R. Flaxman et al.
LANCET GLOBAL HEALTH (2017)
Phase I Trial of Anti-Vascular Endothelial Growth Factor/Anti-angiopoietin 2 Bispecific Antibody RG7716 for Neovascular Age-Related Macular Degeneration
Usha Chakravarthy et al.
OPHTHALMOLOGY RETINA (2017)
Identification of ANGPT2 as a New Gene for Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy in the Chinese and Japanese Populations
Li Ma et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2017)
Targeting Tie2 for Treatment of Diabetic Retinopathy and Diabetic Macular Edema
Peter A. Campochiaro et al.
CURRENT DIABETES REPORTS (2016)
Anti-VEGF Therapy for Retinal Vein Occlusions
Claudio Campa et al.
CURRENT DRUG TARGETS (2016)
Opposing actions of angiopoietin-2 on Tie2 signaling and FOXO1 activation
Minah Kim et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Enhanced Benefit in Diabetic Macular Edema from AKB-9778 Tie2 Activation Combined with Vascular Endothelial Growth Factor Suppression
Peter A. Campochiaro et al.
OPHTHALMOLOGY (2016)
Approaches to modernize the combination drug development paradigm
Daphne Day et al.
GENOME MEDICINE (2016)
Intravitreal AAV2.COMP-Ang1 Prevents Neurovascular Degeneration in a Murine Model of Diabetic Retinopathy
Judd M. Cahoon et al.
DIABETES (2015)
Intraocular pharmacokinetics of intravitreal vascular endothelial growth factor-Trap in a rabbit model
S. J. Park et al.
EYE (2015)
Treatment of Diabetic Macular Edema with an Inhibitor of Vascular Endothelial-Protein Tyrosine Phosphatase That Activates Tie2
Peter A. Campochiaro et al.
OPHTHALMOLOGY (2015)
Molecular pathogenesis of retinal and choroidal vascular diseases
Peter A. Campochiaro
PROGRESS IN RETINAL AND EYE RESEARCH (2015)
Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration
Frank G. Holz et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2015)
Angiopoietin 2 Induces Pericyte Apoptosis via α3β1 Integrin Signaling in Diabetic Retinopathy
Sung Wook Park et al.
DIABETES (2014)
Targeting VE-PTP activates TIE2 and stabilizes the ocular vasculature
Jikui Shen et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Is There Risk of Stroke with Aflibercept? Reply
Jeffrey S. Heier et al.
OPHTHALMOLOGY (2014)
Angiopoietin-1 Suppresses Choroidal Neovascularization and Vascular Leakage
Junyeop Lee et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2014)
Ang-2 upregulation correlates with increased levels of MMP-9, VEGF, EPO and TGFβ1 in diabetic eyes undergoing vitrectomy
Sirpa Loukovaara et al.
ACTA OPHTHALMOLOGICA (2013)
Orchestral actions of angiopoietin-1 in vascular regeneration
Gou Young Koh
TRENDS IN MOLECULAR MEDICINE (2013)
Pharmacokinetics of Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration: A Population Approach
Lu Xu et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2013)
Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular Degeneration
Jeffrey S. Heier et al.
OPHTHALMOLOGY (2012)
Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies
Wolfgang Schaefer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Targeting the ANGPT-TIE2 pathway in malignancy
Hanhua Huang et al.
NATURE REVIEWS CANCER (2010)
Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans
Tim U. Krohne et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2008)
Angiopoietin-1 prevents VEGF-induced endothelial permeability by sequestering src through mDia
Julie Gavard et al.
DEVELOPMENTAL CELL (2008)
Intra and extravascular transmembrane signalling of angiopoietin-1-Tie2 receptor in health and disease
T. Makinde et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2008)
Excess circulating angiopoietin-2 may contribute to pulmonary vascular leak in sepsis in humans
SM Parikh et al.
PLOS MEDICINE (2006)
Pegaptanib sodium for the treatment of neovascular age-related macular degeneration
AA Moshfeghi et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2005)
Angiopoietin-2 enhances retinal vessel sensitivity to vascular endothelial growth factor
Y Oshima et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2004)
Share Paper
